Isoforms of KMTs | Synonyms | Target residues | Kinases | Functional regulation upon phosphorylation | Involved in diseases and signaling pathways | References |
---|---|---|---|---|---|---|
KMT1A | SUV39H1 | Tyr297 | ERBB4 | Activation of enzymatic activity; Chromatin remodeling | NRG-1/ErbB4 signaling | [61] |
Ser391 | CDK2 | |||||
KMT1C | G9a/ EHMT2 | Ser211 | CK2 | Suppression of its binding affinity for RPA70 | DNA damage repair | [63] |
Ser591 | ATM | Inhibition of enzymatic activity; Suppression of the recruitment of DNA repair factors | DNA damage repair | [80] | ||
KMT2A | MLL1 | Ser136 | CK2 | Increase of the affinity of IBMs for the LEDGF/p75 IBD | MLL-rearranged leukemia | [64] |
Ser142 | ||||||
Thr2724 | CK2 | Degradation | MLL-rearranged leukemia | [65] | ||
Ser2726 | ||||||
KMT2B | MLL2 | Thr542 | CDK2 | Chromatin remodeling | Cell cycle | [69] |
KMT2D | MLL4 | Ser1331 | AKT | Inhibition of enzymatic activity | PI3K pathway | [59] |
KMT2E | MLL5 | Thr912 | CDC2 | Activation of enzymatic activity | Cell cycle | [81] |
KMT4 | DOT1L | Ser1105(Mouse) | CDK1 | Inhibition of enzymatic activity | Embryonic stem cell (ESC) differentiation | [73] |
KMT6A | EZH2 | Ser21 | AKT | Inhibition of enzymatic activity | Oncogenesis | [77] |
Ser220 | MELK | Degradation | Natural killer/T-cell lymphoma (NKTL) | [82] | ||
Tyr244 | JAK3 | Promotion of the dissociation of the PRC2 complex | Natural killer/T-cell lymphoma (NKTL) | [83] | ||
Thr261 | CDK5 | Degradation | Pancreatic cancer cell migration and invasion | [84] | ||
Thr311 | AMPK | Disruption of the interaction with SUZ12 | Tumor growth | [85] | ||
Thr350 | CDK4/6 | Activation of enzymatic activity | Psoriasis | [76] | ||
S363 | GSK3β | Inhibition of enzymatic activity | Human breast cancers | [86] | ||
T416 | CDK2 | Chromatin remodeling | Triple-negative breast cancer; Cell cycle | [87] | ||
T492 | CDK1 | Degradation | Lung cancer cell migration and invasion | [88] | ||
Y646 | JAK2 | Degradation | Lymphoma pathogenesis | [89] | ||
KMT6B | EZH1 | Ser560(Mouse) | Unknown | Degradation | Adaptive stress response pathway | [75] |
PRMT1 | Â | Tyr291 | Unknown | Inhibition of enzymatic activity | Mitosis; Tumorigenicity; Radiation response of glioblastoma stem cells | [79] |
Ser297 | Unknown | Activation of enzymatic activity | Inflammation | [78] | ||
PRMT6 | Â | Ser11 | CK2 | Stabilization | Mitosis; Tumorigenicity; Radiation response of glioblastoma stem cells | [79] |
Thr21 | ||||||
KDM2A | CXXC8 FBL7 FBXL11 JHDM1A KIAA1004 | Thr632 | ATM | Disruption of its binding to chromatin | DNA damage repair | [90] |
KDM2B | CXXC2 FBL10 FBLX10 JHDM1B PCCX2 | Ser265 | PKA | Chromatin remodeling | Cell cycle | [91] |
KDM4B | JMJD2B JHDM3B | Ser666 | PKA | Enhance of its binding to SF3B3 | Androgen deprivation | [92] |
Thr305 | ERK | Stabilization | Colon cancer | [93] | ||
Ser352 | ||||||
Ser566 | ||||||
Thr1065 | ||||||
KDM4C | JMJD2C JHDM3C | Ser918 | PKR | Degradation | Glioblastoma Tumorigenesis; Wnt/β-catenin signaling | [94] |
KDM5B | JARID1B | Ser1456 | CDK1 | Disruption of its binding to chromatin | Triple negative breast cancer | [95] |